SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Speaker
David J. Lederer, MD, MS
Associate Professor of Medicine & Epidemiology
Co-Director, NYP PFF Care Center Network ILD program
Division of Pulmonary, Allergy, and Critical Care Medicine
Columbia University Medical Center
New York, NY


Moderator
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Course Director
Fernando Martinez, MD, MS
Professor of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center,
New York, NY

Title
: Interstitial Lung Disease: Recognizing and Managing Progressive Fibrosis
Activity/Course #:
: NCME379
Cost:
: Free
Release/Start Date:
: Jun 01 2019
Expiration Date:
: May 31 2020
Topics:
: Pulmonology
Target Audience:
: Pulmonologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.50 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Early diagnosis and treatment of ILD allows for early initiation of therapy potentially leading to better outcomes. This activity will examine the diagnostic approach to IPF and other progressive fibrosing-interstitial lung diseases, the emerging data, from recent clinical trials, on longer term outcomes for patients with ILD treated with nintedanib/pirfenidone, and how to integrate available data into appropriate initial and long-term treatment strategies for patients with IPF and PF-ILD.

This webcast was recorded live at the Conversations in Pulmonology 2019 Live Virtual Broadcast and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Incorporate a diagnostic approach to IPF and other progressive fibrosing-interstitial lung diseases that incorporates current guidelines and evolving modalities.
  2. Recognize the emerging data, from recent clinical trials, on longer term outcomes for patients with ILD treated with nintedanib/pirfenidone.
  3. Integrate available data into appropriate initial and long-term treatment strategies for patients with IPF and PF-ILD.

 How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.50 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speaker
Dr. Lederer is a consultant for Veracyte, Inc., Pliant Therapeutics, Inc., Bristol-Myers Squibb Company, Galecto Biotech, Galapagos NV, F. Hoffmann-La Roche AG, and Boehringer Ingelheim.

Moderator
Dr. Rahaghi is a consultant and a speaker for Mallinckrodt Pharmaceuticals, Grifols, and Takeda Pharmaceuticals.

Course Director
Dr. Martinez is a Consultant and a Steering Committee Member of AstraZeneca, GlaskoSmithKline, Boehringer Ingelheim, Genetech, RespiVert, Ltd, Sunovion, Teva and Veracyte.

Activity Planning Committe
Gregg Sherman, MD, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.
Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.